LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY

摘要

Disclosed are compounds of Formula (I): and the pharmaceutically acceptable salts thereof, wherein“A”is S—;—SO—,—SO2—,—O—or NRac—, wherein Rac is H, or C1-20 alkyl and R1 through R5 are defined herein. Also disclosed are pharmaceutical formulations comprising a compound of Formula I and methods of treating, managing, or ameliorating diseases amenable to treatment, management, or amelioration by inhibition of LRRK2 kinase activity, for example, Parkinson's disease.